Loading [MathJax]/jax/output/SVG/jax.js
Review Special Issues

Clinical advancements of biologic agents in the treatment of Kawasaki disease based on its pathogenesis

  • Received: 07 March 2025 Revised: 11 May 2025 Accepted: 26 May 2025 Published: 31 May 2025
  • Kawasaki disease (KD), also known as mucocutaneous lymph node syndrome, is an acute febrile systemic vasculitis predominantly affecting children under the age of 5 years. The hallmark of KD is systemic vasculitis, which can lead to coronary artery complications if not promptly treated. Approximately 15%–20% of untreated cases develop coronary artery aneurysms, coronary artery stenosis, or thrombosis, posing significant risks to pediatric health and survival. In recent years, the incidence of KD has shown an upward trend. While intravenous immunoglobulin in combination with aspirin remains the standard first-line therapy for acute KD, some patients exhibit resistance to intravenous immunoglobulin or progress to refractory KD. The rapid advancement of modern biomedicine has led to increased interest in biological agents for KD treatment, yielding promising outcomes.

    Citation: Qi-Ling Yin, You-Qiong Liu, Hui-Min Zhang, Wei-Hua Zhang. Clinical advancements of biologic agents in the treatment of Kawasaki disease based on its pathogenesis[J]. AIMS Allergy and Immunology, 2025, 9(2): 108-122. doi: 10.3934/Allergy.2025008

    Related Papers:

    [1] Sung Woong Cho, Sunwoo Hwang, Hyung Ju Hwang . The monotone traveling wave solution of a bistable three-species competition system via unconstrained neural networks. Mathematical Biosciences and Engineering, 2023, 20(4): 7154-7170. doi: 10.3934/mbe.2023309
    [2] Felicia Maria G. Magpantay, Xingfu Zou . Wave fronts in neuronal fields with nonlocal post-synaptic axonal connections and delayed nonlocal feedback connections. Mathematical Biosciences and Engineering, 2010, 7(2): 421-442. doi: 10.3934/mbe.2010.7.421
    [3] Xixia Ma, Rongsong Liu, Liming Cai . Stability of traveling wave solutions for a nonlocal Lotka-Volterra model. Mathematical Biosciences and Engineering, 2024, 21(1): 444-473. doi: 10.3934/mbe.2024020
    [4] Xiao-Min Huang, Xiang-ShengWang . Traveling waves of di usive disease models with time delay and degeneracy. Mathematical Biosciences and Engineering, 2019, 16(4): 2391-2410. doi: 10.3934/mbe.2019120
    [5] Tong Li, Zhi-An Wang . Traveling wave solutions of a singular Keller-Segel system with logistic source. Mathematical Biosciences and Engineering, 2022, 19(8): 8107-8131. doi: 10.3934/mbe.2022379
    [6] Shiqiang Feng, Dapeng Gao . Existence of traveling wave solutions for a delayed nonlocal dispersal SIR epidemic model with the critical wave speed. Mathematical Biosciences and Engineering, 2021, 18(6): 9357-9380. doi: 10.3934/mbe.2021460
    [7] Zhihong Zhao, Yan Li, Zhaosheng Feng . Traveling wave phenomena in a nonlocal dispersal predator-prey system with the Beddington-DeAngelis functional response and harvesting. Mathematical Biosciences and Engineering, 2021, 18(2): 1629-1652. doi: 10.3934/mbe.2021084
    [8] M. B. A. Mansour . Computation of traveling wave fronts for a nonlinear diffusion-advection model. Mathematical Biosciences and Engineering, 2009, 6(1): 83-91. doi: 10.3934/mbe.2009.6.83
    [9] Tiberiu Harko, Man Kwong Mak . Travelling wave solutions of the reaction-diffusion mathematical model of glioblastoma growth: An Abel equation based approach. Mathematical Biosciences and Engineering, 2015, 12(1): 41-69. doi: 10.3934/mbe.2015.12.41
    [10] Maryam Basiri, Frithjof Lutscher, Abbas Moameni . Traveling waves in a free boundary problem for the spread of ecosystem engineers. Mathematical Biosciences and Engineering, 2025, 22(1): 152-184. doi: 10.3934/mbe.2025008
  • Kawasaki disease (KD), also known as mucocutaneous lymph node syndrome, is an acute febrile systemic vasculitis predominantly affecting children under the age of 5 years. The hallmark of KD is systemic vasculitis, which can lead to coronary artery complications if not promptly treated. Approximately 15%–20% of untreated cases develop coronary artery aneurysms, coronary artery stenosis, or thrombosis, posing significant risks to pediatric health and survival. In recent years, the incidence of KD has shown an upward trend. While intravenous immunoglobulin in combination with aspirin remains the standard first-line therapy for acute KD, some patients exhibit resistance to intravenous immunoglobulin or progress to refractory KD. The rapid advancement of modern biomedicine has led to increased interest in biological agents for KD treatment, yielding promising outcomes.



    The theory of fixed points is one of the interesting areas of research in mathematics. In 1890, Picard [1] established the concept of fixed point theory by using the successive approximations method and proved the existence of solutions of differential equations. In the field of mathematics, many researchers have made their contributions to fixed point theory by applying different types of contraction mappings and spaces. In 1922, Banach [2] proved a "Banach Contraction Principle" which is stated as follows: "A single-valued contractive type mapping on a complete metric space has a unique fixed point". Since then, many mathematicians have generalized in many directions and proved distinct contractive-type fixed point theorems in the framework of metric spaces for single- and multi-valued operations. Some of their findings in different types of metric spaces can be found in [3,4,5,6,7,8,9,10].

    In 1972, Grossman and Katz [11] established an advanced type of calculus called multiplicative calculus by replacing the roles of difference and sum with the roles of division and multiplication, separately. By applying the concept of multiplicative calculus, Bashirov et al. [12] proved the basic theorem of multiplicative calculus and defined the notion of multiplicative metric space (MM-space). The characterization of completeness in MM-space was discussed by Sarwar and Rom [13]. He et al. [14] established some common fixed point theorems for weak commutative mapping on MM-space. In [15], Jiang and Gu proved some common coupled FP results in MM-spaces with applications. For more detail, we shall refer the readers to [16,17,19,20,21,22,23,24,25,26]and the references are therein.

    In the present paper, we prove some new fixed point results for linear-mapping in multiplicative metric spaces under the generalized contraction conditions. Our main results consist of the maximum and minimum types regarding contraction conditions. We also present some demonstrative examples and an application in support of our generalized results to validate our work.

    Definition 2.1. [12] Let W seT, Then, a mapping d:W×WR+ is called a multiplicative metric if it satisfies the following conditions:

    (m1) d(˜p,˜δ)1 and d(˜p,˜δ)=1˜p=˜δ, for all ˜p,˜δW.

    (m2) d(˜p,˜δ)=d(˜δ,˜p) for all ˜p,˜δW.

    (m3) d(˜p,˜δ)d(˜p,˜δ).d(˜δ,˜δ) for all ˜p,˜δ,˜δW.

    A pair (W,d) is said to be an MM-space.

    Example 2.2. [12] Consider W=(R+)ξ containing all ξ-tuples of positive real numbers. Let d:(R+)ξ×(R+)ξR be defined as follows:

    d(˜p,˜δ)=|r1s1||r2s2||rξsξ|,

    where ˜p=(r1,r2,...,rξ), ˜δ=(s1,s2,...,sξ)(R+)ξ, and ||:R+[1,+) is defined as

    |ξ|={ξif ξ1, and 1ξif ξ<1}.

    Then, it is conclusive that all the given conditions of an MM-space are satisfied, and hence ((R+)ξ,d) is an MM-space.

    Definition 2.3. [15,24] Let (W,d) be an MM-space and {pξ} be a sequence in W. Then,

    (ⅰ) pξ is convergent to pW as ξ+ iff d(pξ,p)1 as ξ+.

    (ⅱ) {pξ} is called a multiplicative Cauchy sequence if it holds that for all ε>1, there exists a natural number ξ0N such that d(pξ,pς)<ε for all ξ,ς>ς0.

    (ⅲ) (W,d) is called multiplicative complete if every multiplicative Cauchy sequence in (W,d) is multiplicative convergent in W.

    Lemma 2.4. [24] Let (W,d) be an MM-space and {pξ} be a sequence in W. If a sequence {pξ} is multiplicative convergent, then the multiplicative limit is unique.

    Theorem 2.5. [24] Let (W,d) be an MM-space and sequence {pξ} in W be multiplicative convergent, Then, it is a multiplicative Cauchy sequence.

    In this section, we define and prove some generalized contraction theorems on MM-spaces.

    Definition 3.1. Let (W,d) be an MM-space. A mapping Γ:WW is said to be a Generalized multiplicative contraction (GM-contraction), if there exists ˜λ1,˜λ2,˜λ30 with (˜λ1+4˜λ2+2˜λ3)<1 and satisfying:

    d(Γ˜p,Γ˜δ)(d(˜p,˜δ))˜λ1(d(˜p,Γ˜p)d(˜δ,Γ˜δ) d(˜p,Γ˜δ)d(˜δ,Γ˜p))˜λ2(max{d(˜p,Γ˜p),d(˜δ,Γ˜δ),d(˜p,Γ˜δ),d(˜δ,Γ˜p)})˜λ3, (3.1)

    for all ˜p,˜δW.

    Theorem 3.2. Suppose (W,d) is a complete MM-space and a function Γ:WW is a GM-contraction satisfying (3.1). Then, Γ has a unique fixed point in W.

    Proof: Fix p0 in W, and a sequence {pξ} in W is defined by pξ+1=Γpξ for ξ0. Now, from (3.2),

    d(pξ+1,pξ)=d(Γpξ,Γpξ1) (d(pξ,pξ1))˜λ1(d(pξ,Γpξ)d(pξ1,Γpξ1) d(pξ,Γpξ1)d(pξ1,Γpξ))˜λ2(max{d(pξ,Γpξ),d(pξ1,Γpξ1),d(pξ,Γpξ1),d(pξ1,Γpξ)})˜λ3=(d(pξ,pξ1))˜λ1(d(pξ,pξ+1)d(pξ1,pξ) d(pξ,pξ)d(pξ1,pξ+1))˜λ2(max{d(pξ,pξ+1),d(pξ1,pξ),d(pξ,pξ),d(pξ1,pξ+1)})˜λ3=(d(pξ,pξ1))˜λ1(d(pξ,pξ+1)d(pξ1,pξ)1d(pξ1,pξ+1))˜λ2(max{d(pξ,pξ+1),d(pξ1,pξ),1,d(pξ1,pξ+1)})˜λ3(d(pξ,pξ1))˜λ1(d(pξ,pξ+1)d(pξ1,pξ) d(pξ1,pξ)d(pξ,pξ+1))˜λ2(d(pξ1,pξ)d(pξ,pξ+1))˜λ3=(d(pξ,pξ1))˜λ1((d(pξ,pξ+1))2(d(pξ1,pξ))2)˜λ2(d(pξ1,pξ)d(pξ,pξ+1))˜λ3.

    After simplification, we obtain that

    d(pξ+1,pξ)(d(pξ,pξ1))h,whereh=˜λ1+2˜λ2+˜λ312˜λ2˜λ3<1. (3.2)

    Similarly,

    d(pξ1,pξ)(d(pξ2,pξ1))h,whereh=˜λ1+2˜λ2+˜λ312˜λ2˜λ3<1. (3.3)

    Now, from (3.2) and (3.3), and by induction, we have

    d(pξ,pξ+1)(d(pξ1,pξ))h(d(pξ2,pξ1))h2(d(p0,p1))hξ1,as ξ+. (3.4)

    Hence, the sequence {pξ} in (W,d) is contractive. Now, ξ<ς, and by using the triangular property of (W,d), we have that

    d(pξ,pς)d(pξ,pξ+1)d(pξ+1,pξ+2)d(pς2,pς1)d(pς1,pς)(d(p0,p1))hξ(d(p0,p1))hξ+1(d(p0,p1))hς1(d(p0,p1))hς(d(p0,p1))(hξ+hξ+1++hς1+hς)(d(p0,p1))(hξ1h)1,as ξ+.

    Hence it is show that {pξ} is a Cauchy sequence in (W,d). By the completeness of (W,d), there exists κW, so that limξ+pξ=κ, and therefore

    limξ+d(pξ,κ)=1. (3.5)

    Now, we have to show that Γ(κ)=κ. Then, from (3.1) and (3.5), we have that

    d(κ,Γκ)d(κ,pξ+1)d(pξ+1,Γκ)=d(κ,pξ+1)d(Γpξ,Γκ)d(κ,pξ+1) (d(pξ,κ))˜λ1(d(pξ,Γpξ)d(κ,Γκ) d(pξ,Γκ)d(κ,Γpξ))˜λ2(max{d(pξ,Γpξ),d(κ,Γκ),d(pξ,Γκ),d(κ,Γpξ)})˜λ3=d(κ,pξ+1)(d(pξ,κ))˜λ1(d(pξ,pξ+1)d(κ,Γκ) d((pξ,Γκ)d(κ,pξ+1))˜λ2(max{d(pξ,pξ+1),d(κ,Γκ),d(pξ,Γκ),d(κ,pξ+1)})˜λ3(d(κ,Γκ))2˜λ2+˜λ3as ξ+.

    Hence, we obtain that

    d(κ,Γκ)(d(κ,Γκ))2˜λ2+˜λ3(d(κ,Γκ))(12˜λ2˜λ3)1

    is a contradiction. Hence, we get that d(Γκ,κ)=1 implies that Γκ=κ, which shows that κ is a FP of Γ in (W,d).

    Uniqueness: Suppose μW is another FP of the mapping Γ, so that Γμ=μ. Now, we prove that κ=μ. From the view of (3.1), we have

    d(κ,μ)=d(Γκ,Γμ)(d(κ,μ))˜λ1(d(κ,Γκ)d(μ,Γμ) d(κ,Γμ)d(μ,Γκ))˜λ2(max{d(κ,Γκ),d(μ,Γμ),d(κ,Γμ),d(μ,Γκ)})˜λ3=(d(κ,μ))˜λ1(d(κ,κ)d(μ,μ) d(κ,μ)d(μ,κ))˜λ2(max{d(κ,κ),d(μ,μ),d(κ,μ),d(μ,κ)})˜λ3=(d(κ,μ))(˜λ1+2˜λ2+˜λ3).

    This implies that

    d(κ,μ)(d(κ,μ))(˜λ1+2˜λ2+˜λ3)(d(κ,μ))(1˜λ12˜λ2˜λ3)1,

    is a contradiction. Hence, we get that d(κ,μ)=1 implies that κ=μ. Thus, Γ has a unique fixed point in W.

    If we reduce and use separately the second and third term values of the statement of Theorem 3.2, we get the following two corollaries.

    Corollary 3.3. Let (W,d) be a complete MM-space and let a function Γ:WW satisfy,

    d(Γ˜p,Γ˜δ)(d(˜p,˜δ))˜λ1(d(˜p,Γ˜p)d(˜δ,Γ˜δ))˜λ2(max{d(˜p,Γ˜p),d(˜δ,Γ˜δ)})˜λ3,

    for all ˜p,˜δW and ˜λ1,˜λ2,˜λ30 with (˜λ1+2˜λ2+˜λ3)<1. Then, Γ has a unique FP in W.

    Corollary 3.4. Let (W,d) be a complete MM-space and let a function Γ:WW satisfy,

    d(Γ˜p,Γ˜δ))(d(˜p,˜δ))˜λ1(d(˜δ,Γ˜p)d(˜p,Γ˜δ))˜λ2(max{d(˜p,Γ˜δ),d(˜δ,Γ˜p))})˜λ3,

    for all ˜p,˜δW and ˜λ1,˜λ2,˜λ30 with (˜λ1+2˜λ2+2˜λ3)<1. Then, Γ has a unique FP in W.

    Now we present a supportive example for our first main result.

    Example 3.5. Assume that W=[0,+[, and d:WR is a complete MM-space which is defined as d(˜p,˜δ)=2|˜p˜δ| for all ˜p,˜δW. Now, we define a function Γ:WW by Γ(˜p)=˜p10 for ˜pW. Now, from (3.2), we have

    d(Γ˜p,Γ˜δ)=2|˜p˜δ10|2|7˜p+2˜δ50|=2|28˜p+8˜δ200|=2|10˜p10˜δ+18˜p+18˜δ200|=2|˜p˜δ20+18˜p+18˜δ200|2(|˜p˜δ20|+|18˜p+18˜δ200|)=2|120(˜p˜δ)|2|1200(18˜p+18˜δ)|(2|(˜p˜δ)|)120(2|18˜p+18˜δ10|)120(max{2|9˜p10|,2|9˜δ10|,2|10˜p˜δ10|,2|10˜δ˜p10|})15=(d(˜p,˜δ))120(d(˜p,Γ˜p)d(˜δ,Γ˜δ) d(˜p,Γ˜δ)d(˜δ,Γ˜p))120(max{d(˜p,Γ˜p),d(˜δ,Γ˜δ),d(˜p,Γ˜δ),d(˜δ,Γ˜p)})15.

    Hence, all properties of Theorem 3.2 are satisfied for particular ˜λ1=˜λ2=120 and ˜λ3=15, and Γ has a unique fixed point, that is, Γ(0)=0.

    Now, we present our second main result for minimum condition,

    Theorem 3.6. Let (W,d) be a complete MM-space and let a function Γ:WW satisfy;

    d(Γ˜p,Γ˜δ) (d(˜p,˜δ))˜λ1(d(˜p,Γ˜p) d(˜δ,Γ˜δ) d(˜p,Γ˜δ)d(˜δ,Γ˜p))˜λ2(min{d(˜p,Γ˜p),d(˜δ,Γ˜δ),d(˜p,Γ˜δ),d(˜δ,Γ˜p)})˜λ3, (3.6)

    for all ˜p,˜δW and ˜λ1,˜λ2,˜λ30 with (˜λ1+4˜λ2)<1. Then, Γ has a unique fixed point in W.

    Proof. Fix p0 in W, and a sequence {pξ} in W is defined pξ+1=Γpξfor ξ0. Now, from (3.6),

    d(pξ+1,pξ)=d(Γpξ,Γpξ1) (d(pξ,pξ1))˜λ1(d(pξ,Γpξ)d(pξ1,Γpξ1)d(pξ,Γpξ1).d(pξ1,Γpξ))˜λ2.(min{d(pξ,Γpξ),d(pξ1,Γpξ1),d(pξ,Γpξ1),d(pξ1,Γpξ)})˜λ3=(d(pξ,pξ1))˜λ1(dξ,pξ+1)d(pξ1,pξ)d(pξ,pξ)d(pξ1,pξ+1))˜λ2(min{d(pξ,pξ+1),d(pξ1,pξ),d(pξ,pξ),d(pξ1,pξ+1)})˜λ3=(d(pξ,pξ1))˜λ1(d(pξ,pξ+1)d(pξ1,pξ)1d(pξ1,Γpξ+1))˜λ2(min{d(pξ,pξ+1),d(pξ1,pξ),1,d(pξ1,pξ+1)})˜λ3(d(pξ,ξ1))˜λ1(d(pξ,pξ+1)d(pξ1,pξ)d(pξ1,pξ)d(pξ,Γpξ+1))˜λ2=(d(pξ,pξ1))˜λ1((d(pξ,pξ+1))2(d(pξ1,pξ))2)˜λ2

    After simplification, we obtain that

    d(pξ+1,pξ)(d(pξ,pξ1))h,whereh=˜λ1+2˜λ212˜λ2<1. (3.7)

    Similarly,

    d(pξ1,pξ)(d(pξ2,pξ1))h,whereh=˜λ1+2˜λ212˜λ2<1. (3.8)

    Now, from (3.7) and (3.8) and by induction, we have

    d(pξ,pξ+1)(d(pξ1,pξ))h(d(pξ2,pξ1))h2(d(p0,p1))hξ1,as ξ+. (3.9)

    Hence, the sequence {pξ} in (W,d) is contractive. Now, ξ<ς, and by using the triangular property of (W,d), we have that

    d(pξ,pς)d(pξ,pξ+1)d(pξ+1,pξ+2)d(pς2,pς1)d(pς1,pς)(d(p0,p1))hξ(d(p0,p1))hξ+1(d(p0,p1))hς1(d(p0,p1))hς(d(p0,p1))(hξ+hξ+1++hς1+hς)(d(p0,p1))(hξ1h)1,as ξ,ς+.

    Hence it is shown that {pξ} is a Cauchy sequence in (W,d). By completeness of (W,d), there exists κW, so that limξ+pξ=κ, and therefore

    limξ+d(pξ,κ)=1. (3.10)

    Now, we have to show Γ(κ)=κ. Then, from (3.1) and (3.10), we have that

    d(κ,Γκ)d(κ,pξ+1)d(pξ+1,Γκ)=d(κ,pξ+1)d(Γpξ,Γκ)d(κ,pξ+1)(d(pξ,κ))˜λ1(d(pξ,Γpξ)d(κ,Γκ) d(pξ,Γκ)d(κ,Γpξ))˜λ2(min{d(pξ,Γpξ),d(κ,Γκ),d(pξ,Γκ),d(κ,Γpξ)})˜λ3=d(κ,pξ+1)(d(pξ,κ))˜λ1(d(pξ,pξ+1)d(κ,Γκ) d(pξ,Γκ)d(κ,pξ+1))˜λ2(min{d(pξ,pξ+1),d(κ,Γκ), d(pξ,Γκ),d(κ,pξ+1)})˜λ3(d(κ,Γκ))2˜λ2,as ξ+.

    Hence, we obtain that

    d(κ,Γκ)(d(κ,Γκ))2˜λ2(d(κ,Γκ))(12˜λ2)1,

    is a contradiction. Hence, we get that d(Γκ,κ)=1 implies that Γκ=κ, which shows that κ is a FP of Γ in (W,d).

    Uniqueness: Suppose μ is another fixed point of the mapping Γ in (W,d), so that Γμ=μ. Now, we show that κ=μ. From the view of (3.6),

    d(κ,μ)=d(Γκ,Γμ)(d(κ,μ))˜λ1.(d(κ,Γκ).d(μ,Γμ).d(κ,Γμ).d(μ,Γκ))˜λ2.(min{d(κ,Γκ),d(μ,Γμ),d(κ,Γμ),d(μ,Γκ)})˜λ3=(d(κ,μ))˜λ1.(d(κ,κ).d(μ,μ).d(κ,μ).d(μ,κ))˜λ2.(min{d(κ,κ),d(μ,μ),d(κ,μ),d(μ,κ)})˜λ3=(d(κ,μ))˜λ1+2˜λ2.

    Hence,

    d(κ,μ)(d(κ,μ))˜λ1+2˜λ2(d(κ,μ))(1˜λ12˜λ2)1,

    is a contradiction. Hence, we get that d(κ,μ)=1 implies that κ=μ. Thus, Γ has a unique FP in W.

    If we reduce and use separately the second and third term values of the statement of Theorem 3.6, we get the following two corollaries.

    Corollary 3.7. Let (W,d) be a complete MM-space and let a function Γ:WW satisfy,

    d(Γ˜p,Γ˜p)(d(˜δ,˜δ))˜λ1(d(˜p,Γ˜p)d(˜δ,Γ˜δ))˜λ2(min{d(˜p,Γ˜p),d(˜δ,Γ˜δ)})˜λ3,

    for all ˜p,˜δW and ˜λ1,˜λ2,˜λ30 with (˜λ1+2˜λ2+˜λ3)<1. Then, Γ has a unique fixed point in W.

    Corollary 3.8. Let (W,d) be a complete MM-space and let a function Γ:WW satisfy,

    d(Γ˜p,Γ˜δ)(d(˜p,˜δ))˜λ1(d(˜δ,Γ˜p)d(˜p,Γ˜δ))˜λ2(min{d(˜δ,Γ˜p),d(˜p,Γ˜δ)})˜λ3,

    for all ˜p,˜δW and ˜λ1,˜λ2,˜λ30 with (˜λ1+2˜λ2)<1. Then, a function Γ has a unique fixed point.

    Example 3.9. From Example 3.5, a function Γ is a multiplicative contraction and holds all the conditions of Theorem 3.6 with particular constants ˜λ1=120, ˜λ2=15 and ˜λ3=0. A function Γ has a unique fixed point, that is, 0.

    For the validity of our main results, we present an application of a nonlinear integral equation (NIE) for the existence of a unique solution. Let W=B([c,d],R) be the Banach space of all continuous mappings on [c,d] with supremum norm

    ˜p=sup˜n[c,d]|˜p(˜n)|, where ˜pB([c,d],R),

    and the metric d:W×WR is defined as:

    d(˜p,˜δ)=sup˜n[c,d]|˜p(˜n)˜δ(˜n)|=˜p˜δ,where˜p,˜δB([c,d],R). (4.1)

    The NIE is defined as:

    ˜p(˜n)=dcE(˜n,˜u,˜p(˜u))d˜u, (4.2)

    with ˜n[c,d]R and E:[c,d]×[c,d]×RR.

    Theorem 4.1. Assume that the NIE is defined as in (4.2), and there exists ˜λ(0,1) so that

    Γ˜pΓ˜δ(D(Γ,˜p,˜δ))˜λ, (4.3)

    where

    D(Γ,˜p,˜δ)=min{˜p˜δ,(˜pΓ˜p˜δΓ˜δ ˜pΓ˜δ˜δΓ˜p),max{˜pΓ˜p,˜δΓ˜δ,˜pΓ˜δ,˜δΓ˜p}}. (4.4)

    Then, the NIE (4.2) has a unique solution in W.

    Proof. Define a function Γ:WW by

    Γ˜p(˜n)=dcE(˜n,˜u,˜p(˜u))d˜u,for all ˜pW. (4.5)

    Now, we apply Theorem 3.1 to the integral operator Γ to validate our work. We may have the following three main cases:

    (1) If ˜p˜δ is the minimum term in (4.4), then D(Γ,˜p,˜δ)=˜p˜δ. Now from (4.1) and (4.3), we have that

    d(Γ˜p,Γ˜δ)=Γ˜pΓ˜δ(D(Γ,˜p,˜δ))˜λ=(˜p˜δ)˜λ=(d(˜p,˜δ))˜λ,

    for all ˜p,˜δW. Hence, the operator Γ satisfies all the conditions of Theorem 3.1 with ˜λ=˜λ1 and ˜λ2=˜λ3=0. Thus, Γ has a unique FP in W, which is a unique solution of NIE (4.2).

    (2) If (˜pΓ˜p˜δΓ˜δ˜δΓ˜p˜pΓ˜δ) is the minimum term in (4.4), then

    D(Γ,˜p,˜δ)=(˜pΓ˜p˜δΓ˜δ˜δΓ˜p˜pΓ˜δ).

    Now, from (4.1) and (4.3), we have that

    d(Γ˜p,Γ˜δ)=Γ˜pΓ˜δ(D(Γ,˜p,˜δ))˜λ=(˜pΓ˜p˜δΓ˜δ˜δΓ˜p˜pΓ˜δ)˜λ=(d(˜p,Γ˜p)d(˜δ,Γ˜δ)d(˜p,Γ˜δ)d(˜δ,Γ˜p))˜λ,

    for all ˜p,˜δW. Hence, the operator Γ satisfy all the conditions of Theorem 3.1 with ˜λ=˜λ2 and ˜λ1=˜λ3=0. Thus, Γ has a unique FP in W, which is a unique solution of NIE (4.2).

    (3) If (max{˜pΓ˜p,˜δΓ˜δ,˜δΓ˜p,˜pΓ˜δ}) is the minimum term in (4.4), then

    D(Γ,˜p,˜δ)=max{˜pΓ˜p,˜δΓ˜δ,˜δΓ˜p,˜pΓ˜δ}.

    Now, we may have the following four subcases:

    (ⅰ) If ˜pΓ˜p is the maximum term in {˜pΓ˜p,˜δΓ˜δ,˜δΓ˜p,˜pΓ˜δ}, then D(Γ,˜p,˜δ)=˜pΓ˜p. Now, from (4.1) and (4.3), we have that

    d(Γ˜p,Γ˜δ)=Γ˜pΓ˜δ(D(Γ,˜p,˜δ))˜λ=(˜pΓ˜p)˜λ=(d(˜p,Γ˜p))˜λfor all ˜p,˜δW.

    (ⅱ) If ˜δΓ˜δ is the maximum term in {˜pΓ˜p,˜δΓ˜δ,˜δΓ˜p,˜pΓ˜δ}, then D(Γ,˜p,˜δ)=˜δΓ˜δ. Now, from (4.1) and (4.3), we have that

    d(Γ˜p,Γ˜δ)=Γ˜pΓ˜δ(D(Γ,˜p,˜δ))˜λ=(˜δΓ˜δ)˜λ=(d(˜δ,Γ˜δ))˜λfor all ˜p,˜δW.

    (ⅲ) If ˜δΓ˜p is the maximum term in {˜pΓ˜p,˜δΓ˜δ,˜δΓ˜p,˜pΓ˜δ}, then D(Γ,˜p,˜δ)=˜δΓ˜p. Now, from (4.1) and (4.3), we have that

    d(Γ˜p,Γ˜δ)=Γ˜pΓ˜δ(D(Γ,˜p,˜δ))˜λ=(˜δΓ˜p)˜λ=(d(˜δ,Γ˜p))˜λfor all ˜p,˜δW.

    (ⅳ) If ˜pΓ˜δ is the maximum term in {˜pΓ˜p,˜δΓ˜δ,˜δΓ˜p,˜pΓ˜δ}, then D(Γ,˜p,˜δ)=˜pΓ˜δ. Now, from (4.1) and (4.3), we have that

    d(Γ˜p,Γ˜δ)=Γ˜pΓ˜δ(D(Γ,˜p,˜δ))˜λ=(˜pΓ˜δ)˜λ=(d(˜p,Γ˜δ))˜λfor all ˜p,˜δW.

    Hence, from (ⅰ)–(ⅳ), the operator Γ satisfies all the conditions of Theorem 3.1 with ˜λ=˜λ3 and ˜λ1=˜λ2=0. Thus, Γ has a unique FP in W, which is a unique solution of a NIE (4.2).

    In the present paper, we studied and showed some of the latest generalized fixed point theorems by using the maximum and minimum conditions for single-valued contractive type mappings on MM-spaces with illustrative examples. Our results extended and improved many results existing in the literature of fixed point theory on MM-spaces. Further, we presented an application of an NIE to support our work. This new concept will play a vital role in the theory of fixed point. By using this new concept, one can prove some more generalized fixed point, common fixed point and coincidence point results with the application of different types of integral equations.

    This research received funding from the National Science, Research and Innovation Fund (NSRIF), Thailand.

    The authors declare that they have no conflicts of interest.


    Acknowledgments



    This study was supported by the Natural Science Foundation of Shaanxi Province, China (NO.2020SF-004).

    Conflict of interest



    All authors declare that they have no conflict of interest in relation to this paper.

    Author contributions



    Zhang WH and Yin QL contributed to conception and design of the study; Yin QL wrote the first draft of the manuscript; all authors contributed to editing of the manuscript.

    [1] Miyata K, Miura M, Kaneko T, et al. (2021) Risk factors of coronary artery abnormalities and resistance to intravenous immunoglobulin plus corticosteroid therapy in severe Kawasaki disease: An analysis of post RAISE. Circ Cardiovasc Qual Outcomes 14: e007191. https://doi.org/10.1161/CIRCOUTCOMES.120.007191
    [2] Lei WT, Chang LS, Zeng BY, et al. (2022) Pharmacologic interventions for Kawasaki disease in children: A network meta-analysis of 56 randomized controlled trials. EBioMedicine 78: 103946. https://doi.org/10.1016/j.ebiom.2022.103946
    [3] Kibata T, Suzuki Y, Hasegawa S, et al. (2016) Coronary artery lesions and the increasing incidence of Kawasaki disease resistant to initial immunoglobulin. Int J Cardiol 214: 209-215. https://doi.org/10.1016/j.ijcard.2016.03.017
    [4] Ohnishi Y, Okada S, Kawakami-Miyake A, et al. (2022) Safety and feasibility of infliximab therapy in children with Kawasaki disease who received live vaccinations. Pediatr Infect Dis J 41: e388-e392. https://doi.org/10.1097/INF.0000000000003611
    [5] Tang B, Lo HH, Lei C, et al. (2020) Adjuvant herbal therapy for targeting susceptibility genes to Kawasaki disease: An overview of epidemiology, pathogenesis, diagnosis and pharmacological treatment of Kawasaki disease. Phytomedicine 70: 153208. https://doi.org/10.1016/j.phymed.2020.153208
    [6] Chang L, Yang HW, Lin TY, et al. (2021) Perspective of immunopathogenesis and immunotherapies for Kawasaki disease. Front Pediatr 9: 697632. https://doi.org/10.3389/fped.2021.697632
    [7] Kumrah R, Vignesh P, Rawat A, et al. (2020) Immunogenetics of Kawasaki disease. Clin Rev Allergy Immunol 59: 122-139. https://doi.org/10.1007/s12016-020-08783-9
    [8] Paolini L, Guida F, Calvaruso A, et al. (2024) Endothelial dysfunction: Molecular mechanisms and therapeutic strategies in Kawasaki disease. Int J Mol Sci 25: 13322. https://doi.org/10.3390/ijms252413322
    [9] Rife E, Gedalia A (2020) Kawasaki disease: An update. Curr Rheumatol Rep 22: 75. https://doi.org/10.1007/s11926-020-00941-4
    [10] Wang W, Zhu L, Li X, et al. (2023) Emerging evidence of microbial infection in causing systematic immune vasculitis in Kawasaki disease. Front Microbiol 14: 1313838. https://doi.org/10.3389/fmicb.2023.1313838
    [11] Chang LY, Lu CY, Shao PL, et al. (2014) Viral infections associated with Kawasaki disease. J Formos Med Assoc 113: 148-154. https://doi.org/10.1016/j.jfma.2013.12.008
    [12] McCrindle BW, Rowley AH, Newburger JW, et al. (2017) Diagnosis, treatment, and long-term management of Kawasaki disease: A scientific statement for health professionals from the American Heart Association. Circulation 135: e927-e999. https://doi.org/10.1161/CIR.0000000000000484
    [13] Bordea MA, Costache C, Grama A, et al. (2022) Cytokine cascade in Kawasaki disease versus Kawasaki-like syndrome. Physiol Res 71: 17-27. https://doi.org/10.33549/physiolres.934672
    [14] Zhang H, Song HB, Wang DX, et al. (2022) Correlation between the level of inflammatory cytokines and prognosis in children with IVIG-sensitive Kawasaki disease and IVIG-resistant Kawasaki disease. Pak J Med Sci 38: 1165-1169. https://doi.org/10.12669/pjms.38.5.5408
    [15] Jone PN, Tremoulet A, Choueiter N, et al. (2024) Update on diagnosis and management of Kawasaki disease: A scientific statement from the American Heart Association. Circulation 150: e481-e500. https://doi.org/10.1161/CIR.0000000000001295
    [16] Yamaji N, da Silva Lopes K, Shoda T, et al. (2019) TNF-α blockers for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev 8: CD012448. https://doi.org/10.1002/14651858.CD012448.pub2
    [17] Li D, Li X, Dou W, et al. (2021) The effectiveness of infliximab for Kawasaki disease in children: Systematic review and meta-analysis. Transl Pediatr 10: 1294-1306. https://doi.org/10.21037/tp-20-482
    [18] Chen J, Liao J, Xiang L, et al. (2023) Current knowledge of TNF-α monoclonal antibody infliximab in treating Kawasaki disease: A comprehensive review. Front Immunol 14: 1237670. https://doi.org/10.3389/fimmu.2023.1237670
    [19] Portman MA, Olson A, Soriano B, et al. (2011) Etanercept as adjunctive treatment for acute Kawasaki disease: Study design and rationale. Am Heart J 161: 494-499. https://doi.org/10.1016/j.ahj.2010.12.003
    [20] Kabbaha S, Milano A, Aldeyab MA, et al. (2023) Infliximab as a second-line therapy for children with refractory Kawasaki disease: A systematic review and meta-analysis of randomized controlled trials. Br J Clin Pharmacol 89: 49-60. https://doi.org/10.1111/bcp.15547
    [21] Koizumi K, Hoshiai M, Katsumata N, et al. (2018) Infliximab regulates monocytes and regulatory T cells in Kawasaki disease. Pediatr Int 60: 796-802. https://doi.org/10.1111/ped.13555
    [22] Ishii M, Ebato T, Kato H (2020) History and future of treatment for acute stage Kawasaki disease. Korean Circ J 50: 112-119. https://doi.org/10.4070/kcj.2019.0290
    [23] Hur G, Song MS, Sohn S, et al. (2019) Infliximab treatment for intravenous immunoglobulin-resistant Kawasaki disease: A multicenter study in Korea. Korean Circ J 49: 183-191. https://doi.org/10.4070/kcj.2018.0214
    [24] Li X, Tang Y, Ding Y, et al. (2021) Higher efficacy of infliximab than immunoglobulin on Kawasaki disease, a meta-analysis. Eur J Pharmacol 899: 173985. https://doi.org/10.1016/j.ejphar.2021.173985
    [25] Portman MA, Dahdah NS, Slee A, et al. (2019) Etanercept with IVIG for acute Kawasaki disease: A randomized controlled trial. Pediatrics 143: e20183675. https://doi.org/10.1542/peds.2018-3675
    [26] Ohashi R, Fukazawa R, Watanabe M, et al. (2013) Etanercept suppresses arteritis in a murine model of kawasaki disease: A comparative study involving different biological agents. Int J Vasc Med 2013: 543141. https://doi.org/10.1155/2013/543141
    [27] Sagiv E, Slee A, Buffone A, et al. (2023) Etanercept with IVIG for acute Kawasaki disease: A long-term follow-up on the EATAK trial. Cardiol Young 33: 613-618. https://doi.org/10.1017/S1047951122001470
    [28] Tremoulet AH (2018) Adjunctive therapies in Kawasaki disease. Int J Rheum Dis 21: 76-79. https://doi.org/10.1111/1756-185X.13208
    [29] Lee Y, Wakita D, Dagvadorj J, et al. (2015) IL-1 signaling is critically required in stromal cells in Kawasaki disease vasculitis mouse model: Role of both IL-1α and IL-1β. Arterioscler Thromb Vasc Biol 35: 2605-2616. https://doi.org/10.1161/ATVBAHA.115.306475
    [30] Cavalli G, Colafrancesco S, Emmi G, et al. (2021) Interleukin 1α: A comprehensive review on the role of IL-1α in the pathogenesis and treatment of autoimmune and inflammatory diseases. Autoimmun Rev 20: 102763. https://doi.org/10.1016/j.autrev.2021.102763
    [31] Maniscalco V, Abu-Rumeileh S, Mastrolia MV, et al. (2020) The off-label use of anakinra in pediatric systemic autoinflammatory diseases. Ther Adv Musculoskelet Dis 12: 1759720X20959575. https://doi.org/10.1177/1759720X20959575
    [32] Mastrolia MV, Abbati G, Signorino C, et al. (2021) Early anti IL-1 treatment replaces steroids in refractory Kawasaki disease: Clinical experience from two case reports. Ther Adv Musculoskelet Dis 13: 1759720X211002593. https://doi.org/10.1177/1759720X211002593
    [33] De Rose DU, Campi F, Maddaloni C, et al. (2025) Off-label use of anakinra in inflammatory conditions in neonates and infants up to 3 months of age: A case series and a review of the literature. Paediatr Drugs 27: 293-305. https://doi.org/10.1007/s40272-024-00679-x
    [34] Bossi G, Codazzi AC, Vinci F, et al. (2022) Efficacy of anakinra on multiple coronary arteries aneurysms in an infant with recurrent Kawasaki disease, complicated by macrophage activation syndrome. Children 9: 672. https://doi.org/10.3390/children9050672
    [35] Ferrara G, Giani T, Caparello MC, et al. (2020) Anakinra for treatment-resistant Kawasaki disease: Evidence from a literature review. Paediatr Drugs 22: 645-652. https://doi.org/10.1007/s40272-020-00421-3
    [36] Malcova H, Milota T, Strizova Z, et al. (2021) Interleukin-1 blockade in polygenic autoinflammatory disorders: Where are we now?. Front Pharmacol 11: 619273. https://doi.org/10.3389/fphar.2020.619273
    [37] Yang J, Jain S, Capparelli EV, et al. (2021) Anakinra treatment in patients with acute Kawasaki disease with coronary artery aneurysms: A phase I/IIa trial. J Pediatr 243: 173-180.e8. https://doi.org/10.1016/j.jpeds.2021.12.035
    [38] Lind-Holst M, Hartling UB, Christensen AE (2019) High-dose anakinra as treatment for macrophage activation syndrome caused by refractory Kawasaki disease in an infant. BMJ Case Rep 12: e229708. https://doi.org/10.1136/bcr-2019-229708
    [39] Shafferman A, Birmingham JD, Cron RQ (2014) High dose anakinra for treatment of severe neonatal Kawasaki disease: A case report. Pediatr Rheumatol Online J 12: 26. https://doi.org/10.1186/1546-0096-12-26
    [40] Gambacorta A, Buonsenso D, De Rosa G, et al. (2020) Resolution of giant coronary aneurisms in a child with refractory Kawasaki disease treated with anakinra. Front Pediatr 8: 195. https://doi.org/10.3389/fped.2020.00195
    [41] Sánchez-Manubens J, Gelman A, Franch N, et al. (2017) A child with resistant Kawasaki disease successfully treated with anakinra: A case report. BMC Pediatr 17: 102. https://doi.org/10.1186/s12887-017-0852-6
    [42] Burns JC, Koné-Paut I, Kuijpers T, et al. (2017) Review: Found in translation: International initiatives pursuing interleukin-1 blockade for treatment of acute Kawasaki disease. Arthritis Rheumatol 69: 268-276. https://doi.org/10.1002/art.39975
    [43] Martins FR, Azevedo AC, Ganhão S, et al. (2023) Anakinra and hepatotoxicity in pediatric rheumatology: A case series. Pediatr Rheumatol Online J 21: 112. https://doi.org/10.1186/s12969-023-00891-y
    [44] Malcova H, Strizova Z, Milota T, et al. (2021) IL-1 Inhibitors in the treatment of monogenic periodic fever syndromes: From the past to the future perspectives. Front Immunol 11: 619257. https://doi.org/10.3389/fimmu.2020.619257
    [45] Renner C (2019) 20 years of rituximab treatment: What have we learnt?. Future Oncol 15: 4119-4121. https://doi.org/10.2217/fon-2019-0694
    [46] Lucchini E, Zaja F, Bussel J (2019) Rituximab in the treatment of immune thrombocytopenia: What is the role of this agent in 2019?. Haematologica 104: 1124-1135. https://doi.org/10.3324/haematol.2019.218883
    [47] Sauvaget E, Bonello B, David M, et al. (2012) Resistant Kawasaki disease treated with anti-CD20. J Pediatr 160: 875-876. https://doi.org/10.1016/j.jpeds.2012.01.018
    [48] Tacke CE, Burgner D, Kuipers IM, et al. (2012) Management of acute and refractory Kawasaki disease. Expert Rev Anti Infect Ther 10: 1203-1215. https://doi.org/10.1586/eri.12.101
    [49] Wu Y, Liu FF, Xu Y, et al. (2019) Interleukin-6 is prone to be a candidate biomarker for predicting incomplete and IVIG nonresponsive Kawasaki disease rather than coronary artery aneurysm. Clin Exp Med 19: 173-181. https://doi.org/10.1007/s10238-018-00544-5
    [50] Ling J, Xie F, Zhou Q, et al. (2024) Case series on the efficacy and safety of tocilizumab in IVIG-resistant Kawasaki disease: A retrospective analysis of five patients. J Inflamm Res 17: 10991-10998. https://doi.org/10.2147/JIR.S479879
    [51] Cui HY, Hu CP (2022) Recent research on the application of biologics in the treatment of multisystem inflammatory syndrome in children after SARS-CoV-2 infection. Zhongguo Dang Dai Er Ke Za Zhi 24: 216-222. https://doi.org/10.7499/j.issn.1008-8830.2111005
    [52] Porritt RA, Chase Huizar C, Dick EJ, et al. (2021) Inhibition of IL-6 in the LCWE mouse model of Kawasaki disease Inhibits acute phase reactant serum amyloid a but fails to attenuate vasculitis. Front Immunol 12: 630196. https://doi.org/10.3389/fimmu.2021.630196
    [53] Barman P, Pilania RK, Cv G, et al. (2024) Treatment intensification in Kawasaki disease-current perspectives. Expert Rev Clin Immunol 20: 1179-1191. https://doi.org/10.1080/1744666X.2024.2378900
    [54] Nozawa T, Imagawa T, Ito S (2017) Coronary-artery aneurysm in tocilizumab-treated Children with Kawasaki's Disease. N Engl J Med 377: 1894-1896. https://doi.org/10.1056/NEJMc1709609
    [55] Bachlava E, Loukopoulou S, Karanasios E, et al. (2016) Management of coronary artery aneurysms using abciximab in children with Kawasaki disease. Int J Cardiol 220: 65-69. https://doi.org/10.1016/j.ijcard.2016.06.062
    [56] Jone PN, Tapia D, Davidson J, et al. (2015) Successful treatment of myocardial infarction in an infant with Kawasaki disease. Semin Cardiothorac Vasc Anesth 19: 255-259. https://doi.org/10.1177/1089253215573328
    [57] Garcia Verde MJ, Martinez Roca C, Yanez Gomez P, et al. (2016) Abciximab in refractory Kawasaki disease. Eur J Hosp Pharm 23: A33-A34. https://doi.org/10.1136/ejhpharm-2016-000875.76
  • This article has been cited by:

    1. Alan Dyson, Existence and Uniqueness of Traveling Fronts in Lateral Inhibition Neural Fields with Sigmoidal Firing Rates, 2020, 19, 1536-0040, 2194, 10.1137/20M1311697
  • Reader Comments
  • © 2025 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Metrics

Article views(255) PDF downloads(13) Cited by(0)

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog